Celgene's Revlimid Delays Cancer Progression in Study BusinessWeek The 459-patient study focused on patients ages 75 and younger who were ineligible for stem-cell transplant, a way of treating the bone marrow cancer. Celgene is applying for approval in Europe for use of Revlimid as a first treatment option and as a ... ASH 2011 Myelodysplastic Syndromes Update – Day 1 & Day 2 Phase III Study with REVLIMID(R) Continuous Therapy Demonstrates Statistically ... |
